METHODS
The design, methods, and clinical results of the SYNTAX trial have been published previously (1, 3, 4) . All patients gave written informed consent, and locally appointed ethics committees and regulatory agencies approved the study protocol. withdrew from the study, or were lost to follow-up.
Covariates for the growth curve models included the To evaluate whether between-group differences in health status were clinically significant, we created cumulative response curves that describe the proportion of patients (by treatment group) who achieved health status improvement of a given magnitude (12) .
An additional analysis was performed in which the SAQ-AF score was treated as a categorical vari- Table 1) . At baseline, according to the SAQ-AF scale, 11% of the patients had daily angina, 27% had weekly angina, 39% had monthly angina, and 22% had no angina. Completion rates for the SAQ and SF-36 are summarized in Online Table 1 . In general, completion rates were high and similar for both treatment groups through 3 years of follow-up. At 5 years, there was a slight decline in compliance with QOL follow-up, with rates of 70% to 75% for the SAQ and 75% to 80% for the SF-36. When we compared patients who did and did not respond to the QOL surveys at 5 years, nonresponders were older, more likely to smoke, and more likely to have had a prior myocardial infarction (Online Table 2 ). In addition, nonresponders had greater physical limitations at baseline as determined on the basis of both the SAQ and the SF-36.
DISEASE-SPECIFIC HEALTH STATUS.
Changes in disease-specific health status over time and mean differences between treatment groups are summarized in the Central Illustration and Table 2 . months and 1 year; these changes were largely sustained at 3 and 5 years (Online Table 3 ). Compared with CABG, patients assigned to DES-PCI had faster health status improvement with higher scores on the SAQ-PL, SAQ-QOL, and SAQ treatment satisfaction scales at 1 month. These differences were not sustained, however, and CABG resulted in improved scores on the SAQ-AF and SAQ-QOL scales at 1-year follow-up. At 3-year follow-up, there were no differences in disease-specific health status between treatment groups; however, at 5-year follow-up, there were small but statistically significant differences favoring CABG on both the SAQ-AF and the SAQ-PL subscales (mean differences of 2.1 and 3.0 points, respectively).
Results were generally similar when these analyses were repeated using longitudinal growth curve models to account for missing data (Online Table 4) and when the SAQ-AF scale was analyzed as a categorical variable (Figure 2 ). In particular, the proportion of patients who were angina free was significantly greater with CABG than with DES-PCI at Table 3 ). Changes in generic health To determine whether method of revascularization made a difference in long-term quality of life for patients with 3-vessel or left main coronary artery disease, we compared Seattle Angina Questionnaire (SAQ) domain subscale scores for (A) angina frequency, (B) physical limitations, (C) quality of life, and (D) treatment satisfaction among 1,800 patients randomized to coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial. Although both interventions were associated with sustained quality-of-life benefits, long-term angina relief was enhanced with CABG surgery. Values are mean differences (95% confidence intervals). *According to analysis of covariance models adjusted for baseline score. †p < 0.05. Table 1 . 
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SUBGROUP ANALYSES. The estimated effect of CABG versus DES-PCI on the SAQ-AF scale within prespecified subgroups is shown in Figure 4A Table 5 ).
Antianginal medication use rates over time are summarized in Online Table 6 . There were no signif- trial (23) . 
